Dasatinib vs imatinib -newly diagnosed CML cp
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
You are here
Nilotinib versus imatinib -newly diagnosed CML
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
TKI's in CML: Passing the Baton
Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Passing the Baton
Jason Gotlib, MD, MS
September 1, 2010
Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Passing the Baton
Jason Gotlib, MD, MS
September 1, 2010
Blocking rogue gene could stop the spread of most cancers
Published: 24/01/2011 12:27:29
Scientists at the University of East Anglia have discovered a rogue gene which – if blocked by the right drugs – could stop cancer in its tracks.Published today by the journal Oncogene, the discovery is a breakthrough in our understanding of how cancer spreads. It is hoped the research will lead to new drugs that halt the critical late stage of the disease when cancer cells spread to other parts of the body.
Published: 24/01/2011 12:27:29
Scientists at the University of East Anglia have discovered a rogue gene which – if blocked by the right drugs – could stop cancer in its tracks.Published today by the journal Oncogene, the discovery is a breakthrough in our understanding of how cancer spreads. It is hoped the research will lead to new drugs that halt the critical late stage of the disease when cancer cells spread to other parts of the body.
BELA Trial: Similar Rate of CCyR With Bosutinib vs Imatinib in Newly Diagnosed Patients With Ph-Positive CML-CP
BELA Trial: Similar Rate of CCyR With Bosutinib vs Imatinib in Newly Diagnosed Patients With Ph-Positive CML-CP
Posting Date: December 11, 2010
BELA: international, multicenter, randomized, open-label phase III study[1]
BELA Trial: Similar Rate of CCyR With Bosutinib vs Imatinib in Newly Diagnosed Patients With Ph-Positive CML-CP
Posting Date: December 11, 2010
BELA: international, multicenter, randomized, open-label phase III study[1]
Seeking the causes of and solutions to imatinib resistance in CML
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
D Bixby and M Talpaz
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, US
read PDF here:
http://www.nature.com/leu/journal/v25/n1/pdf/leu2010238a.pdf
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
D Bixby and M Talpaz
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, US
read PDF here:
http://www.nature.com/leu/journal/v25/n1/pdf/leu2010238a.pdf
First-line dasatinib, nilotinib sustain their edge over imatinib
First-Line Dasatinib, Nilotinib Sustain Edge Over Imatinib
Elsevier Global Medical News. 2010 Dec 21,
First-Line Dasatinib, Nilotinib Sustain Edge Over Imatinib
Elsevier Global Medical News. 2010 Dec 21,
ASH 2010 - pick of abstracts
Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
Elsevier Global Medical News. 2010 Dec 6, JS MacNeil
Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
Elsevier Global Medical News. 2010 Dec 6, JS MacNeil
Oncologystat- CML The Changing Landscape: Interview with Prof. Apperley-Parts 1 and 2
CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
ASH 2010 - Orlando
Chronic Myeloid Leukemia: An Historical Perspective
Chronic Myeloid Leukemia: An Historical Perspective
Michael W. Deininger